Hospital
Saint Vincent Health Center
Saint Vincent Health Center was paid $18.19M by Medicaid between Jan 2018 and Dec 2024, across 270 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoSAINT VINCENT HEALTH CENTER
ERIE, PA 16544
ERIE, PA 16544
33aNPI1861435042assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.19M
24GClaims610,911
24DCodes billed270
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#17 of 154
Median peer was paid$2.82M
This provider vs. median6.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 204 | $13K | |
| 2019 | 1,249 | $34K | |
| 2020 | 52,607 | $1.26M | |
| 2021 | 228,154 | $6.21M | |
| 2022 | 102,152 | $3.19M | |
| 2023 | 118,764 | $3.78M | |
| 2024incomplete | 107,781 | $3.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 29,007 | 27,650 | $3.82M |
| G0378 | Hospital observation service, per hour | 20% | 4,523 | 4,244 | $3.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 25,646 | 24,712 | $2.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 24,803 | 24,177 | $2.17M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.7% | 5,055 | 4,942 | $488K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 3,962 | 3,926 | $439K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 3,072 | 2,972 | $434K |
| G0379 | Direct admission of patient for hospital observation care | 1.5% | 418 | 362 | $278K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 43,499 | 37,740 | $276K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 9,066 | 8,436 | $207K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 14,248 | 13,878 | $202K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 47,588 | 40,892 | $189K |
258 more codes
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 4,050 | $177K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,613 | $150K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,109 | $142K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,344 | $124K |
| 80076 | <1% | 19,574 | $123K | |
| 84484 | <1% | 15,061 | $123K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,194 | $80K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 800 | $78K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 384 | $77K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,173 | $69K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,829 | $68K |
| 83735 | <1% | 14,485 | $65K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,576 | $58K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 241 | $57K |
| 0002A | <1% | 1,259 | $55K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,579 | $54K |
| 84703 | <1% | 6,422 | $53K | |
| 0001A | <1% | 1,323 | $52K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,286 | $50K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 922 | $47K |
| 83690 | <1% | 12,654 | $45K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 479 | $42K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 342 | $40K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 426 | $37K |
| 81001 | <1% | 17,390 | $37K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 275 | $37K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 77 | $36K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,246 | $33K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 402 | $28K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 504 | $28K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 563 | $27K |
| 80053 | Comprehensive metabolic panel | <1% | 3,722 | $27K |
| 72141 | <1% | 141 | $26K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,931 | $25K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 65 | $25K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 248 | $25K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,054 | $24K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 367 | $23K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 661 | $23K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 118 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,353 | $22K |
| 93971 | <1% | 430 | $20K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 68 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,926 | $18K |
| 76642 | <1% | 480 | $18K | |
| 70498 | <1% | 235 | $18K | |
| J3490 | Unclassified drugs | <1% | 3,978 | $17K |
| 71250 | <1% | 331 | $16K | |
| 70496 | <1% | 222 | $16K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 593 | $14K |
| 93970 | <1% | 232 | $13K | |
| 87040 | <1% | 1,441 | $13K | |
| 70486 | <1% | 238 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,446 | $13K |
| 93296 | <1% | 1,219 | $13K | |
| 77065 | Tomosynthesis, mammo | <1% | 234 | $13K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 413 | $13K |
| 96376 | <1% | 1,297 | $12K | |
| 93976 | <1% | 210 | $12K | |
| 88342 | <1% | 496 | $12K | |
| 97597 | <1% | 456 | $11K | |
| 93975 | <1% | 143 | $11K | |
| 77066 | Tomosynthesis, mammo | <1% | 155 | $11K |
| 87631 | <1% | 83 | $10K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 39 | $10K |
| 73610 | <1% | 608 | $10K | |
| 87081 | <1% | 2,118 | $9K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 350 | $9K |
| 76801 | <1% | 321 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,563 | $9K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,088 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 343 | $9K |
| 72100 | <1% | 464 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 565 | $9K |
| 93017 | <1% | 484 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 562 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 286 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 366 | $9K |
| 74174 | <1% | 73 | $9K | |
| 81025 | <1% | 2,897 | $8K | |
| 83605 | <1% | 2,400 | $8K | |
| 73630 | <1% | 843 | $8K | |
| 80050 | General health panel | <1% | 182 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 736 | $8K |
| 80299 | <1% | 390 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 973 | $7K |
| 85379 | <1% | 1,165 | $7K | |
| 73030 | <1% | 567 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 533 | $7K |
| 90715 | <1% | 990 | $7K | |
| 83880 | <1% | 801 | $6K | |
| 73562 | <1% | 475 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 348 | $6K |
| 80061 | Lipid panel | <1% | 1,208 | $6K |
| 84702 | <1% | 505 | $6K | |
| 76536 | <1% | 128 | $6K | |
| 87088 | <1% | 1,222 | $6K | |
| 73130 | <1% | 548 | $6K | |
| 70491 | <1% | 86 | $5K | |
| 72131 | <1% | 103 | $5K | |
| 81003 | <1% | 1,943 | $5K | |
| 43235 | <1% | 50 | $5K | |
| 73502 | <1% | 368 | $5K | |
| 93922 | <1% | 241 | $4K | |
| 86850 | <1% | 1,088 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 58 | $4K |
| 88341 | <1% | 79 | $4K | |
| 84999 | <1% | 1,090 | $4K | |
| 10060 | <1% | 58 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 92 | $3K |
| 73110 | <1% | 352 | $3K | |
| 93880 | <1% | 41 | $3K | |
| 73700 | <1% | 53 | $3K | |
| 72040 | <1% | 233 | $3K | |
| 74019 | <1% | 271 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,253 | $3K |
| 86900 | <1% | 1,300 | $3K | |
| 0003A | <1% | 111 | $3K | |
| 86901 | <1% | 1,298 | $3K | |
| 73560 | <1% | 251 | $3K | |
| 96367 | <1% | 368 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 605 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 89 | $2K |
| C1769 | Guide wire | <1% | 122 | $2K |
| 82728 | <1% | 289 | $2K | |
| 96417 | <1% | 42 | $2K | |
| 85730 | <1% | 1,068 | $2K | |
| 85610 | <1% | 1,617 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,058 | $2K |
| 82550 | <1% | 606 | $2K | |
| 85027 | <1% | 807 | $2K | |
| 0223U | <1% | 13 | $2K | |
| C1781 | Mesh (implantable) | <1% | 12 | $2K |
| 80320 | <1% | 253 | $2K | |
| 87210 | <1% | 475 | $2K | |
| 87077 | <1% | 409 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,019 | $2K |
| 82962 | <1% | 2,723 | $2K | |
| 74018 | <1% | 157 | $2K | |
| 77062 | <1% | 68 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,316 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 512 | $1K |
| 84439 | <1% | 279 | $1K | |
| 73590 | <1% | 111 | $1K | |
| 76775 | <1% | 41 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 282 | $1K |
| 84100 | <1% | 642 | $1K | |
| 83540 | <1% | 258 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 278 | $1K |
| 77061 | <1% | 67 | $1K | |
| 87070 | <1% | 369 | $1K | |
| 12001 | <1% | 77 | $1K | |
| 73090 | <1% | 120 | $1K | |
| 97161 | <1% | 285 | $1K | |
| 87186 | <1% | 288 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,135 | $1K |
| 82607 | <1% | 164 | $1K | |
| 73080 | <1% | 110 | $1K | |
| 88304 | <1% | 310 | $977.90 | |
| 87075 | <1% | 213 | $927.00 | |
| 77336 | <1% | 27 | $913.95 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,948 | $899.64 |
| 73140 | <1% | 119 | $880.12 | |
| 94729 | <1% | 27 | $824.38 | |
| 76870 | <1% | 29 | $819.92 | |
| 88313 | <1% | 12 | $815.76 | |
| 93225 | <1% | 41 | $800.53 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,547 | $783.43 |
| 83550 | <1% | 226 | $757.76 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,226 | $734.24 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 384 | $725.76 |
| 87205 | <1% | 320 | $703.62 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,680 | $703.24 |
| 12002 | <1% | 26 | $695.81 | |
| 99152 | <1% | 276 | $668.71 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,546 | $663.09 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,181 | $601.91 |
| 85652 | <1% | 500 | $575.69 | |
| 72128 | <1% | 12 | $560.33 | |
| 97165 | <1% | 287 | $543.20 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,023 | $539.74 |
| 86140 | <1% | 494 | $536.47 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 322 | $534.93 |
| 72070 | <1% | 30 | $529.25 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 578 | $468.86 |
| 80329 | <1% | 102 | $467.86 | |
| 86920 | <1% | 27 | $402.36 | |
| 86308 | <1% | 77 | $376.73 | |
| 59025 | Fetal non-stress test | <1% | 145 | $365.63 |
| 82010 | <1% | 123 | $317.90 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,129 | $314.03 |
| 12011 | <1% | 12 | $311.85 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,898 | $306.01 |
| 71101 | <1% | 26 | $282.39 | |
| 82553 | <1% | 80 | $277.33 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 119 | $269.37 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 562 | $255.54 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,354 | $241.49 |
| 36430 | <1% | 27 | $236.47 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $220.53 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 324 | $219.03 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 159 | $212.67 |
| 95816 | <1% | 37 | $209.08 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 58 | $208.54 |
| 83615 | <1% | 37 | $197.42 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 206 | $196.23 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 66 | $182.73 |
| 97162 | <1% | 103 | $179.25 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 119 | $176.20 |
| 94761 | <1% | 463 | $169.56 | |
| 94060 | <1% | 14 | $169.25 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,819 | $158.31 |
| 82746 | <1% | 25 | $143.52 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,666 | $142.42 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 465 | $138.73 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,707 | $136.57 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,055 | $133.06 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 661 | $127.89 |
| 82140 | <1% | 62 | $111.13 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,549 | $109.98 |
| 88307 | <1% | 30 | $101.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,466 | $98.10 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 233 | $92.35 |
| 84550 | <1% | 16 | $84.94 | |
| S0030 | Injection, metronidazole, 500 mg | <1% | 104 | $84.48 |
| 88173 | <1% | 12 | $75.13 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 479 | $73.75 |
| A9270 | Non-covered item or service | <1% | 32,650 | $70.45 |
| 85045 | <1% | 15 | $66.96 | |
| 84145 | <1% | 56 | $48.86 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 25 | $26.46 |
| 88108 | <1% | 14 | $23.12 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 170 | $20.96 |
| 94760 | <1% | 81 | $17.99 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 25 | $17.04 |
| 88311 | <1% | 14 | $13.62 | |
| 85018 | <1% | 21 | $13.42 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,805 | $12.83 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 90 | $10.80 |
| 84132 | <1% | 12 | $6.97 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 868 | $1.60 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 29 | $0.89 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 33 | $0.55 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 5,380 | $0.26 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 94 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 115 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 185 | $0.00 |
| 82077 | 0% | 28 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 16 | $0.00 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 57 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 552 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 177 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 13 | $0.00 |
| 0004A | 0% | 36 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 78 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 76 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 18 | $0.00 |
| 0054A | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLARK, CHRISTOPHER (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Christopher Clark, DDS, II, PLLC | Greensboro, NC | $1.90M |
| DR. Christopher J Clark DDS and Associates | Leland, NC | $1.55M |
| Christopher Clark DDS PA | Bladenboro, NC | $983K |
| Premiere Spine and Sports Medicine LLC | Hagerstown, MD | $291K |
| Woodbury Dental Partners | Woodbury, TN | $61K |
| Wellness Associates, LLC | Rock Springs, WY | $54K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.